None
Quote | Cortexyme Inc. (NYSE:CRTX)
Last: | $ |
---|---|
Change Percent: | 13.96% |
Open: | $54.18 |
Close: | $61.07 |
High: | $62.00 |
Low: | $52.7152 |
Volume: | 170,815 |
Last Trade Date Time: | 02/12/2020 04:42:12 pm |
News | Cortexyme Inc. (NYSE:CRTX)
Alzheimer’s drug developer Cortexyme ( NASDAQ: CRTX ) announced on Wednesday that the company would change its corporate name and ticker symbol with effect from August. Accordingly, Cortexyme ( CRTX ) will be branded as Quince Therapeutics next month, and its ti...
New ticker symbol (Nasdaq: QNCX) to initiate trading on August 1, 2022 Cortexyme, Inc. (Nasdaq: CRTX) today announced that the company’s planned corporate name change to Quince Therapeutics is expected take effect on Monday, August 1, 2022. In conjunction with the cor...
Message Board Posts | Cortexyme Inc. (NYSE:CRTX)
Subject | By | Source | When |
---|---|---|---|
It's not if, just when the shorts get | trendzone | investorshub | 04/21/2022 7:10:17 PM |
Simple gap and trap right before their offering | BooDog | investorshub | 04/14/2022 12:15:28 PM |
It's a gapper! Nice early volume. | BooDog | investorshub | 04/14/2022 11:48:33 AM |
I'm in. Time to go up! | weedisgreen | investorshub | 12/30/2021 1:39:34 AM |
4 Swing Trade Ideas #LGVN ?? #$CRTX ?? | da_stock_analyst | investorshub | 12/26/2021 10:48:59 PM |
News, Short Squeeze, Breakout and More Instantly...
New ticker symbol (Nasdaq: QNCX) to initiate trading on August 1, 2022 Cortexyme, Inc. (Nasdaq: CRTX) today announced that the company’s planned corporate name change to Quince Therapeutics is expected take effect on Monday, August 1, 2022. In conjunction with the cor...
Once daily dose of COR588 over 10-day period well-tolerated with no serious adverse events observed Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on advancing therapeutics for rare and degenerative diseases, today reported the successful ...
Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on advancing therapeutics for rare and degenerative diseases, today announced new preclinical data demonstrating the efficacy of the company’s 3CLpro inhibitor, COR803, for treatment of coronavirus...